DOW JONES26,957.59-123.77 -0.46%
S&P 5003,116.39-11.82 -0.38%
NASDAQ8,980.78+15.16 0.17%

Cantor Fitzgerald Assumes Galmed Pharmaceuticals at Overweight, Lowers Price Target To $14

Cantor Fitzgerald analyst Kristen Kluska assumes Galmed Pharmaceuticals (NASDAQ:GLMD) with a Overweight rating and lowers price target from $59 to $14.

Benzinga · 01/30/2020 12:12

Cantor Fitzgerald analyst Kristen Kluska assumes Galmed Pharmaceuticals (NASDAQ:GLMD) with a Overweight rating and lowers price target from $59 to $14.